Compared to teriflunomide, ponesimod showed benefit for magnetic resonance imaging (MRI) outcomes in relapsing multiple sclerosis.

ADS-5102, the extended release capsule form of amantadine, may clinically benefit walking speed in patients with multiple sclerosis.

In secondary progressive multiple sclerosis, amiloride, fluoxetine, and rizuole treatments do not translate into long-term reduction in atrophy rates.

Baseline levels of ubiquitin C-terminal hydrolase L1 in cerebral spinal fluid may be predictive of long term multiple sclerosis progression.

The terminal complement inhibitor eculizumab reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD).

Ozanimod may be a safe and well-tolerated treatment for relapsing forms of multiple sclerosis.

Individuals with relapsing-remitting MS who respond suboptimally to DMT may experience improvement with the addition of an SSRI.

The smartphone-based Symbol Digit Modalities Test is a reliable tool for assessment of cognitive function in patients with multiple sclerosis.

Researchers analyzed whether hypertension onset occurs at an earlier age in individuals with multiple sclerosis who were born post-1965.

Ofatumumab was found to have greater efficacy than teriflunomide for the treatment of patients with newly diagnosed relapsing multiple sclerosis.

Effectiveness of disease modifying therapies for multiple sclerosis was shown to be associated with shorter disease duration and lower relapse rate.

Youths with multiple sclerosis rate activities and participation as more important life domains than disease-related impairments.

Among patients with multiple sclerosis, a history of migraine may not be associated with worse disability or neurological function.

The International Multiple Sclerosis Microbiome study noted significant multiple sclerosis linked changes in gut microbiota composition and function.

Patients with MS treated with peginterferon beta-1a or intramuscular interferon beta 1a may experience real world treatment benefits.

Study findings showed vitamin D levels to be sufficient in two-thirds of participants assessed with multiple sclerosis, likely due to supplementation.

Natalizumab was more effective than fingolimod or BRACETD in reducing relapses in rapidly evolving severe relapsing-remitting multiple sclerosis.

No causal associations found between hypertension, systolic/diastolic blood pressures, high/low density lipoproteins, or type 2 diabetes on multiple sclerosis risk.

Patients with neuromyelitis optica spectrum disorder who experience relapses use more pain medication than non-relapsing patients.

Risks for suicidal ideation and depressive symptoms are not different between patients with progressive and relapsing-remitting multiple sclerosis.

Multiple sclerosis patients are more prepared and ready to use telemedicine than their physicians during the COVID-19 pandemic.

In this case study presented at ACTRIMS 2020, researchers reported on data from a patient with Crohn disease and ankylosing spondylitis who developed autoimmune encephalitis while receiving infliximab.

A network of gut bacteria species may be associated with host genetic factors that increase susceptibility to multiple sclerosis.

More patients with early relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab experienced confirmed disability improvement than disability worsening.

The onset of hyperlipidemia may occur earlier in patients with multiple sclerosis.

Patients who have been diagnosed with and treated for multiple sclerosis (MS) have an increased risk for any type of infection, with the highest risk being for renal tract infections.

Researchers sought to find any genetic variants associated with migraine or MS that could be identified from genome-wide association studies.

Fatigue, anemia, pain, and sleep disorders form part of the prodrome in MS.

Home telehealth may be a feasible and safe option for veterans with multiple sclerosis who have difficulty accessing services from the VA or community services.

Patients with vs without multiple sclerosis were found to be at increased risk for several cardiac events.